AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE
Akari TX /
NEW YORK and LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc(NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on …
[Read more...] about Akari Therapeutics Strengthens Board with Two Senior Industry Appointments
Akari TX /
Last three patients enrolled into the Phase II COBALT trial on the new dosing regimen (45 mg per Day) saw a more rapid decline in LDH than those in the original …
Akari TX /
NEW YORK and LONDON (GLOBE NEWSWIRE) October 18, 2017 / Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and …
Akari TX /
NEW YORK and LONDON, October 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and …
Akari TX /
Plans to start Coversin Phase III in PNH in Q1 2018 NEW YORK and LONDON, September 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), a …
[Read more...] about Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
